Table 4 Comparison of Monday and Friday groups before and after propensity score matching
Patients undergoing surgery on Mon. and Fri. (n = 437) | P value | Propensity score-matched patients (n = 334) | P value | |||||
|---|---|---|---|---|---|---|---|---|
Mon. group (n = 233) | Fri. group (n = 204) | Mon. group (n = 167) | Fri. group (n = 167) | |||||
Age, years (median, IQR) | 70 (62–77) | 69 (62–77) | 0.978 | 70 (62–77) | 69 (62–77) | 0.855 | ||
Gender (n, %) | 1.000 | 1.000 | ||||||
Male | 155 (66.5) | 135 (66.2) | 110 (65.9) | 111 (66.5) | ||||
Female | 78 (33.5) | 69 (33.8) | 57 (34.1) | 56 (33.5) | ||||
Time period (n, %) | 0.244 | 0.181 | ||||||
2004–2010 | 104 (44.6) | 79 (38.7) | 61 (36.5) | 74 (44.3) | ||||
2011–2017 | 129 (55.4) | 125 (61.3) | 106 (63.5) | 93 (55.7) | ||||
BMI, kg/m2 (median, IQR) | 22.7 (20.9–24.5) | 22.5 (20.4–24.8) | 0.333 | 22.6 (21.0–24.5) | 22.5 (20.7–25.0) | 0.935 | ||
Diabetes mellitus (n, %) | 0.896 | 1.000 | ||||||
Absent | 197 (84.6) | 171 (83.8) | 139 (83.2) | 140 (83.8) | ||||
Present | 36 (15.4) | 33 (16.2) | 28 (16.8) | 27 (16.2) | ||||
COPD (n, %) | 1.000 | 0.620 | ||||||
Absent | 220 (94.4) | 192 (94.1) | 160 (95.8) | 157 (94.1) | ||||
Present | 13 (5.6) | 12 (5.9) | 7 (4.2) | 10 (6.0) | ||||
Hemoglobin, g/dl (median, IQR) | 12.7 (11.7–13.9) | 1 2.7 (11.3–13.7) | 0.358 | 12.6 (11.7–13.9) | 12.8 (11.6–13.9) | 0.848 | ||
Albumin, g/dl (median, IQR) | 4.1 (3.9–4.4) | 4.0 (3.7–4.3) | 0.009 | 4.1 (3.8–4.3) | 4.1 (3.8–4.3) | 0.799 | ||
CEA, ng/ml (median, IQR) | 1.5 (0.9–2.5) | 1.6 (0.9–2.4) | 0.829 | 1.5 (0.9–2.3) | 1.6 (0.9–2.5) | 0.920 | ||
CA19-9, U/ml (median, IQR) | 9.4 (6.0–15.3) | 9.4 (6.0–16.6) | 0.482 | 9.4 (6.5–15.0) | 9.3 (6.0–16.0) | 0.608 | ||
Impairment of respiratory function (n, %) | 0.543 | 0.907 | ||||||
Absent | 152 (65.2) | 139 (68.1) | 114 (68.3) | 112 (67.1) | ||||
Present | 81 (34.8) | 65 (31.9) | 53 (31.7) | 55 (32.9) | ||||
Clinical tumor depth (n, %) | 0.763 | 0.720 | ||||||
cT1 | 124 (53.2) | 115 (56.4) | 94 (56.3) | 104 (62.3) | ||||
cT2 | 53 (22.8) | 39 (19.1) | 36 (21.6) | 31 (18.6) | ||||
cT3 | 33 (14.2) | 32 (15.7) | 23 (13.8) | 21 (12.6) | ||||
cT4 | 23 (9.9) | 18 (8.8) | 14 (8.4) | 11 (6.6) | ||||
Clinical lymph node metastasis (n, %) | 0.672 | 0.701 | ||||||
cN0 | 181 (77.7) | 215 (74.5) | 133 (79.6) | 136 (81.4) | ||||
cN1 | 40 (17.2) | 72 (18.6) | 24 (14.4) | 24 (14.4) | ||||
cN2 | 11 (4.7) | 25 (5.4) | 9 (5.4) | 5 (3.0) | ||||
cN3 | 1 (0.4) | 3 (1.5) | 1 (0.6) | 2 (1.2) | ||||
Clinical TNM stage (n, %) | 0.486 | 0.868 | ||||||
I | 161 (69.1) | 141 (69.1) | 120 (71.9) | 126 (75.5) | ||||
IIA | 16 (6.9) | 13 (6.4) | 10 (6.0) | 9 (5.4) | ||||
IIB | 20 (8.6) | 11 (5.4) | 13 (7.8) | 10 (6.0) | ||||
III | 36 (15.5) | 39 (19.1) | 24 (14.4) | 22 (13.2) | ||||
Operative procedure (n, %) | 0.658 | 1.000 | ||||||
Distal gastrectomy | 163 (70.0) | 148 (72.6) | 123 (73.7) | 122 (73.1) | ||||
Proximal gastrectomy | 3 (1.3) | 1 (0.5) | 0 | 1 (0.6) | ||||
Total gastrectomy | 67 (28.8) | 55 (27.0) | 44 (26.4) | 44 (26.4) | ||||
Operative approach (n, %) | 0.099 | 0.909 | ||||||
Open | 107 (45.9) | 77 (37.8) | 59 (35.3) | 61 (36.5) | ||||
Laparoscopic | 126 (54.1) | 127 (62.3) | 108 (64.7) | 106 (63.5) | ||||
Lymph node dissection (n, %) | 0.924 | 1.000 | ||||||
D1/D1+ | 122 (52.4) | 108 (52.9) | 96 (57.5) | 97 (58.1) | ||||
D2 or more | 111 (47.6) | 96 (47.1) | 71 (42.5) | 70 (41.9) | ||||